Holen Sie sich die Stockscreener-App
31.81
1.05%
0.36
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$31.45
Offen:
$31.51
24-Stunden-Volumen:
119.45K
Relative Volume:
0.06
Marktkapitalisierung:
$3.07B
Einnahmen:
$610.16M
Nettoeinkommen (Verlust:
$-532.93M
KGV:
-5.7536
EPS:
-5.5287
Netto-Cashflow:
$-442.30M
1W Leistung:
+5.27%
1M Leistung:
+4.85%
6M Leistung:
-6.91%
1J Leistung:
-42.32%
1-Tages-Spanne:
$31.37
$31.88
1-Wochen-Bereich:
$29.57
$32.10
52-Wochen-Spanne:
$25.81
$57.99
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
31.82 | 3.03B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.74 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.18 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.12 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
329.04 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Does Ultragenyx Pharmaceutical Inc. fit your quant trading modelJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - newser.com
Will Ultragenyx Pharmaceutical Inc. stock benefit from upcoming earnings reports2025 Big Picture & Community Trade Idea Sharing Platform - newser.com
Sentiment analysis tools applied to Ultragenyx Pharmaceutical Inc.Market Sentiment Review & Safe Capital Growth Stock Tips - newser.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Can Ultragenyx Pharmaceutical Inc. (UP0) stock hold up in economic slowdownJuly 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Ultragenyx Pharmaceutical Inc. stock prediction for this weekWeekly Trade Review & Reliable Trade Execution Plans - newser.com
What sentiment indicators say about Ultragenyx Pharmaceutical Inc. stockCPI Data & Capital Protection Trade Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) - MarketBeat
What moving averages say about Ultragenyx Pharmaceutical Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Does Ultragenyx Pharmaceutical Inc. show high probability of reboundWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Predicting Ultragenyx Pharmaceutical Inc. trend using moving averagesJuly 2025 Chart Watch & Safe Entry Point Identification - newser.com
What drives Ultragenyx Pharmaceutical Inc stock priceTechnical Analysis Insights & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Wealth Enhancement Advisory Services LLC Takes $353,000 Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Bank of America Securities Remains Bullish on Ultragenyx Pharmaceutical (RARE) - Yahoo Finance
Pattern recognition hints at Ultragenyx Pharmaceutical Inc. upsideWeekly Volume Report & High Conviction Buy Zone Picks - newser.com
Why Ultragenyx Pharmaceutical Inc. (UP0) stock signals breakout potentialJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
How to read the order book for Ultragenyx Pharmaceutical Inc.Share Buyback & Free Daily Entry Point Trade Alerts - newser.com
Ultragenyx Pharmaceutical Inc. stock trend outlook and recovery path2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Will Ultragenyx Pharmaceutical Inc. (UP0) stock outperform energy sector in 2025Watch List & High Accuracy Swing Entry Alerts - newser.com
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
62,232 Options & 34,564 RSUs: Ultragenyx Grants Inducement Award to New Hire, Grant Date Sep 30, 2025 - Stock Titan
Ultragenyx Pharmaceutical (RARE): Valuation Perspectives Following Regulatory Milestones and Pipeline Progress - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Strategic Leadership Transition with Eric Olson - Sahm
Using RSI to spot recovery in Ultragenyx Pharmaceutical Inc.Weekly Investment Recap & Smart Money Movement Tracker - newser.com
Tools to monitor Ultragenyx Pharmaceutical Inc. recovery probabilityAnalyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
How to monitor Ultragenyx Pharmaceutical Inc. with trend dashboards2025 Short Interest & High Return Trade Guides - newser.com
How Might Ultragenyx (RARE) Leverage Dealmaking Expertise to Shape Its Long-Term Growth Strategy? - Yahoo Finance
Ultragenyx (RARE) Poised for Positive Developments, Says JPMorga - GuruFocus
Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline - Insider Monkey
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical Progress by 8+ Global Leaders – DelveInsight | Featuring Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co., Ltd., GC Biopharma Corp, D - The Globe and Mail
Ultragenyx Pharmaceutical Hits Day High with Strong 8.12% Intraday Surge - Markets Mojo
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
United States Osteogenesis Imperfecta Treatment Market - openPR.com
Ultragenyx appoints Eric Olson as chief business officer By Investing.com - Investing.com Nigeria
Revolution Medicines hires Mirati, ALX vet Sandler - biocentury.com
7 Most Promising Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Ultragenyx appoints Eric Olson as chief business officer and executive vice president - MarketScreener
Ultragenyx appoints Eric Olson as chief business officer - Investing.com India
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - GlobeNewswire
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
2.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):